Loading...
Loading...
On Tuesday, AstraZeneca Plc AZN said the survival results did not reach statistical significance in the overall trial population in the TROPION-Lung01 phase 3 trial . Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients treated with at least one prior line of therapy . Also Read: AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion .
In the pre-specified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel, the current standard of care chemotherapy. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo DSKYF DSNKY and being jointly developed by Daiichi Sankyo and AstraZeneca. The final analysis of OS builds on the PFS results presented at the European Society for Medical Oncology 2023 Congress, which showed that datopotamab deruxtecan demonstrated a statistically significant improvement in PFS in the overall trial population and a clinically meaningful PFS benefit in patients with nonsquamous NSCLC.
The safety profile of datopotamab deruxtecan in TROPION-Lung01 was consistent with the previous analysis, includi.
